ABBVAbbVie
$285.65+28% 1Y
$285.65
$197.3852 weeks$288.97
ABBV in its own filings
Nothing in ABBV's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
316
Events found in the filings · across 1,516 filings · the record starts in 2012
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 15, 2026
Most recent filing · Form 8-K
- Record starts
- Jul 2, 2012
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Jan 6, 2027
- Change in certifying accountant2 occurrences
- 2013-03-19
- Security removed from listing or deregistered5 occurrences · usually a matured note or preferred class, not the common shares
- 2024-06-03
- Material impairment2 occurrences
- 2025-01-10
- SEC comment-letter activity38 occurrences
- 2022-10-20
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 15, 2026Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. …Director or officer change · Form 8-K
- Oct 5, 2026Guidance Including the Impact of Acquired IPR&D and Milestones Expense.Earnings release · press release
- Sep 3, 2026AbbVie Completes Acquisition of Apogee Therapeutics.Regulation FD disclosure · press release
- Aug 18, 2026On August 18, 2026, AbbVie Inc. (“AbbVie”) completed its previously announced underwritten public offering (the “Notes Offering”) of $500,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of its 4.500% senior notes due …Other event · Form 8-K
- Aug 5, 2026On August 4, 2026, AbbVie Inc. (“AbbVie”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II …Other event · Form 8-K
- Jul 31, 2026AbbVie Reports Second-Quarter 2026 Financial Results.Earnings release · press release
- Jul 6, 2026Guidance Including the Impact of Acquired IPR&D and Milestones Expense.Earnings release · press release
- Apr 29, 2026AbbVie Reports First-Quarter 2026 Financial Results.Earnings release · press release
- Apr 3, 2026Guidance Including the Impact of Acquired IPR&D and Milestones Expense.Earnings release · press release
- Mar 4, 2026On March 4, 2026, AbbVie Inc. (“AbbVie”) completed its previously announced underwritten public offering (the “Notes Offering”) of $750,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “Floating Rate Notes”), $1,500,000,000 aggregate principal amount of its 3.775% senior notes due …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Stocks that buy back more than they dilute
Drug Manufacturers, General
The closest names by size in the same industry